Innovus Pharma CEO Provides Shareholder Update
Management Files Year Ending 2015 Financials
(firmenpresse) - SAN DIEGO, CA -- (Marketwired) -- 04/04/16 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases is pleased to provide a shareholder update for the year ending 2015 and beginning of 2016.
"2015 marks our second year of revenue generation and along with the beginning of 2016 has been a transformative time for Innovus Pharma as we continued our acquisition streak to bring in more revenues and products along with the expansion of our commercial partnerships," said Dr. Damaj President & CEO of the Company.
Below are the additional accomplishments of the Company during 2015 and the beginning of 2016:
Zestra®, EjectDelay® , Sensum+®,Zestra Glide®, Vesele®, Androferti®, BTH® Testosterone, BTH® HGA, BTH® Vision, BTH® Blood Sugar, BTH® GCBE, BTH® Colon Cleans, BTH® Ketones.
(Fluticare™ OTC (Fluticasone propionate NS), Androvit® and Urocis® XR
®
®
Product sold over $1.3 M in 2014 and over $2.2 M in 2015.
Completed acquisition in March 2016
Eight commercial partnerships signed with over $5000M in potential sales milestones plus royalties in 60 countries
Repaid all outstanding and due debt
Raised close to $2.5M
"With all the progress and growth the Company is doing, we've initiated our plan for a potential uplisting to the NYSE-MKT exchange market with a goal of uplisting in 2016," continued Dr. Damaj
The Company will have a shareholder update call on:
When: Wednesday, April 6, 2016 4:05 EDT/1:05 PDT
Length: ~ 15 minute presentation followed by a 20 minute Question and Answer session
Dial in number: 530-881-1212
Meeting ID: 615-253-385#
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to , ; ; ; ; ; ; ; .
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products.. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company
Reuven Rubinson
Vice President of Finance
858.964-5123
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2016 - 14:00 Uhr
Sprache: Deutsch
News-ID 461619
Anzahl Zeichen: 0
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Innovus Pharma CEO Provides Shareholder Update"
steht unter der journalistisch-redaktionellen Verantwortung von
Innovus Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
